12:00 AM
 | 
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Hsp90 inhibitor: Preliminary Phase II data

Preliminary data from an open-label, international Phase II trial in 112 patients with advanced NSCLC who failed >=2 prior lines of chemotherapy showed that 70 mg/m 2 IV AUY922 produced 13 partial responses. The most common adverse events reported were diarrhea, visual and nausea....

Read the full 196 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >